Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Phenylephrine
Drug ID BADD_D01762
Description Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil,[L9413] and induce local vasoconstriction.[A187370] The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s.[A187376] Phenylephrine was granted FDA approval in 1939.[L9413]
Indications and Usage Phenylephrine is mainly used to treat nasal congestion, but may also be useful in treating hypotension and shock, hypotension during spinal anaesthesia, prolongation of spinal anaesthesia, paroxysmal supraventricular tachycardia, symptomatic relief of external or internal hemorrhoids, and to increase blood pressure as an aid in the diagnosis of heart murmurs.
Marketing Status Prescription
ATC Code C01CA06; R01AA04; R01AB01; R01BA03; S01FB01; S01GA05
DrugBank ID DB00388
KEGG ID D08365
MeSH ID D010656
PubChem ID 6041
TTD Drug ID D0O6IU
NDC Product Code 42961-205; 0498-3331; 57218-710; 0498-3330
Synonyms Phenylephrine | (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol | Metasympatol | Mezaton | Phenylephrine Hydrochloride | Phenylephrine Tannate | Tannate, Phenylephrine | Metaoxedrin | Neo-Synephrine | Neo Synephrine | Neosynephrine
Chemical Information
Molecular Formula C9H13NO2
CAS Registry Number 59-42-7
SMILES CNCC(C1=CC(=CC=C1)O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal distension07.01.04.0010.024295%
Abdominal pain07.01.05.0020.006074%
Abdominal pain upper07.01.05.003--
Acute myocardial infarction24.04.04.001; 02.02.02.0010.021258%Not Available
Acute pulmonary oedema22.01.03.005; 02.05.02.0040.009111%Not Available
Agitation19.06.02.001; 17.02.05.012--
Aphasia19.21.01.001; 17.02.03.0010.006074%
Apnoea22.02.01.0010.024295%
Arrhythmia02.03.02.001--Not Available
Arteriospasm coronary24.04.04.005; 02.02.02.005--Not Available
Ataxia17.02.02.001; 08.01.02.0040.006074%
Atrioventricular block02.03.01.002--Not Available
Atrioventricular block second degree02.03.01.0050.009111%
Blood pressure decreased13.14.03.0020.009111%Not Available
Blood pressure increased13.14.03.0050.009111%Not Available
Bradycardia02.03.02.0020.057701%Not Available
Bronchospasm10.01.03.012; 22.03.01.0040.006074%
Cardiac arrest02.03.04.0010.003961%
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.003961%Not Available
Cerebral infarction24.04.06.002; 17.08.01.0040.009111%Not Available
Chest pain22.02.08.003; 08.01.08.002; 02.02.02.0110.009111%Not Available
Corneal oedema06.04.02.001--Not Available
Death08.04.01.001--
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.009111%
Dyspnoea02.01.03.002; 22.02.01.004--
Extrasystoles02.03.02.003--Not Available
Extravasation08.01.03.008--Not Available
Eye pain06.08.03.002--
Gastrointestinal disorder07.11.01.001--Not Available
Headache17.14.01.0010.018221%
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages